And the results of that trial were published last August (2017): Title: Exenatide once weekly versus placebo in Parkinsons disease: a randomised, double-blind, placebo-controlled trial Authors: Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y, Aviles-Olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, Tebbs S, Foltynie T Journal: Lancet 2017 Aug 3
In plain English, men receiving testosterone were no more likely to suffer a heart attack, stroke or cardiovascular death than men receiving placebo
A licensed provider should determine which option, if either, is appropriate
Here's what we've learned to investigate first: Product Purity and Source: This is the number one suspect
Impact of inulin and oligofructose on gastrointestinal peptides
Concomitant use of semaglutide with insulin or insulin secretagogues may result in hypoglycemia, and a dose reduction in the concomitant medication may be necessary